Drug Profile
Research programme: p38 MAP kinase inhibitors - Bayer
Latest Information Update: 10 Oct 2006
Price :
$50
*
At a glance
- Originator Bayer
- Class
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Osteoporosis; Rheumatoid arthritis
Most Recent Events
- 10 Oct 2006 Discontinued - Preclinical for Osteoporosis in USA (unspecified route)
- 10 Oct 2006 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 21 Sep 2001 New profile